Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00268554
NCT00268554CompletedNot Applicable

Enhancement of Postocclusive Reactive Hyperaemia

Radboud University Medical Center2 sites in 1 country12 target enrollmentStarted: December 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
12
Locations
2
Primary Endpoint
forearm blood flow
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to determine whether dipyridamole enhances postocclusive reactive hyperaemia by increasing extracellular adenosine concentrations during ischemia and reperfusion. Furthermore we hypothesize that dipyridamole augments postocclusive reactive hyperaemia by increasing adenosine receptor stimulation.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •healthy volunteers between 18 and 50 years

Exclusion Criteria

  • •none specified

Outcomes

Primary Outcomes

forearm blood flow

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
Effects of Dexmedetomidine on Modulation of Perioperative Blood Glucose and Related HormonesDexmedetomidineBlood Glucose
NCT03788538Zhuan Zhang75
Completed
Phase 4
The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human EndotoxemiaEndotoxemia
NCT01091571Radboud University Medical Center30
Completed
Phase 4
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?Ischemia-Reperfusion InjuryAtherosclerosis
NCT00457405Radboud University Medical Center10
Completed
Phase 3
Aggrenox Prevention of Access StenosisKidney Failure
NCT00067119National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)649
Terminated
Not Applicable
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)Peripheral Arterial Disease
NCT00906035University of Pennsylvania25